Bloomberg Law
May 6, 2021, 5:26 PM

U.S. Call to Waive Vaccine Patents Said to Snarl Immunity Effort

Ian Lopez
Ian Lopez
Senior Reporter

The success of an international waiver of patent protections on Covid-19 vaccines largely hangs on whether the U.S. forces its companies to share manufacturing specifications and may not be the harbinger of global immunization it’s cracked up to be, critics say.

Patent industry participants were caught off guard by U.S. Trade Representative Katherine Tai’s announcement Wednesday that the Biden administration supports waiving international intellectual property protections on Covid-19 vaccines. Stocks for vaccine producers Pfizer, BioNtech, Moderna, and Johnson & Johnson dropped after news of the administration’s position came out.

The proposal is now before the World Trade Organization for consideration ...

Learn more about Bloomberg Law or Log In to keep reading:

Learn About Bloomberg Law

AI-powered legal analytics, workflow tools and premium legal & business news.

Already a subscriber?

Log in to keep reading or access research tools.